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ABSTRACT OF DISSERTATION

CANCER PHYLOGENETIC ANALYSIS BASED ON RNA-SEQ DATA
Studying tumor evolution is a major task to understand the biological mechanism
of carcinogenesis, develop new cancer therapies, and prevent drug resistance. We
focus on two important questions in tumor evolution. The first question is to quantify intra-tumor heterogeneity, where multiple subclones of tumor cells with distinct
transcriptomic profiles. Another question is to estimate the temporal order of alteration of key cancer pathways during tumor evolution. We present a new statistical
method to 1) reconstruct the evolutionary history and population frequency of the
subclonal lineages of tumor cells and 2) infer temporal order of pathway alterations
in tumor evolution for each individual patient based on RNA-seq data. Our method
uses a Bayesian nonparametric prior and nested stick-breaking process to allow for
evolutional trees of infinite nodes, and to identify cell population frequencies which
have the highest likelihood of generating the observed RNA-seq data. Markov Chain
Monte Carlo method based on slice sampling is incorporated to perform Bayesian
inference. Based on the constructed evolutional trees, a patient-specific pathway
analysis is performed to identify enriched pathways that are altered in the earlier and
later phases of tumor evolution of that patient. Simulations and real data analysis
demonstrate that the proposed method reliably recover the phylogenetic chain and
population frequency of the subclonal lineages of tumor cells and accurately infer the

temporal order of pathway alterations for individual patient.
KEYWORDS: Tumor evolution, Phylogenetic analysis, Gene expression, RNA-seq
counts, Bayesian nonparametric model, Nested stick-breaking process
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Chapter 1 Introduction

1.1

History of research on tumor evolution

Carcinogenesis is a complex process which involves a complicated evolution process in
a number of key biological pathways and processes. Many types of tumors are highly
heterogeneous containing multiple distinct populations of tumor cells, each with their
own complement of alterations. This intra-tumor heterogeneity arises because tumors
evolve over time and different descendants of the original cell acquire new mutations,
which they then pass on to their progeny (Kuipers, 2015). A better understanding
of the process tumor evolution is very important to study the biological mechanism
of cancer development and to inform new therapeutic targets.
A lot of effort has been put into the research of the tumor evolution process.
In 1976, some initial applied colon evolutionary models have been proposed by Peter
Nowell to understand tumor growth and treatment failure and the phenomenon of increased tumor aggressiveness that occurs during the natural history of advanced solid
tumors (Nowell 1976). By applying these models, Peter Nowell noted that tumors
arise from a single ’mutated’ cell and that biological and clinical progression results
from subsequent additional alterations, giving rise to more aggressive subpopulations
within the original neoplastic clone (Nowell 1976). In the early 1980s, Harris and
colleagues concluded that the generation of the metastatic clones arose at a 101,000
fold higher rate than the generation of stable mutations conferring drug resistance
by investigating the generation of metastatic subclones from a mouse sarcoma cell
line (Harris, Chambers et al. 1982). Subsequently, the same group found that a
melanoma cell line named B16F10 acquired resistance to methotrexate at a higher
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rate than the B16F1 cell line with low metastatic potential, suggesting a common
mechanism responsible for metastatic outgrowth and drug resistance and a common
phenomena that cooccur in epithelial malignancies tumor evolution (Cilio, Dick et
al. 1987).
Besides the models of tumor evolution with sequentially ordered somatic mutations in driver genes, there is more and more recent evidence suggesting that branched
evolutionary tumor growth may contribute to be quantitative analyses both within
a primary tumor and between primary and metastatic tumor sites. Shah and his
colleagues investigated a case and illustrated the temporal order of pathway alterations in advanced invasive lobular carcinoma of the breast tumor evolution through
whole-genome sequencing (Shah, Morin et al. 2009). Navin and colleagues studied
the tumor evaluation through separating tumor cells based on their DNA content,
termed sector ploidy profiling and DNA copy number analysis (Navin, Krasnitz et al.
2010). Charles and colleagues analyzed multiple regions of 2 primary clear-cell renal
carcinomas and associated metastatic sites (Gerlinger, Rowan et al. 2012). They
detected branched evolutionary growth with evidence of convergent evolution, with
multiple recurrent, yet distinct, inactivating mutations occurring in the same tumor
suppressor genes in different branches.

1.2

Phylogenetic analysis of tumor evolution

The application of evolutionary principles to cancers has blossomed into a field in
which a rich foundation of theory and methods for interpreting complicated tumor
evolution (Altrock, Liu et al. 2015), with the method of applying phylogenetic analysis to understand tumor evolution process being one of the hottest tumor evolution
research topics. As tumor phylogenetic has gained in popularity, research on phylogenetic now tends to become to be high-impact studies. Phylogenetics might prove
2

valuable for making sense of tumor progression processes since cancer is an evolutionary phenomenon which led to the insight of computational methods for reconstructing
evolutionary processes. Tsao and the coworkers inferred a tree model of the evolution
of tumor by using microsatellite markers (Tsao, Zhang et al. 1998). After a decade,
this type of analysis has exploded to become a new field known as tumor phylogenetics, which aims to use genomic variations to reconstruct tumor evolution through produced evolutionary tree. These approaches potentially allow for uncertainty among
the space of possible trees explaining a data set (de Bruin, McGranahan et al. 2014).
This basic framework leads to the diversity in tumor phylogenetics methods, including
but limited to cross-cohort studies of many tumors, studies of single-cell variability
in single tumors, single-patient studies of regional bulk genomic assays and the type
or types of genomic data profiled (Pennington, Smith et al. 2007).
The diversity also includes variation by mathematical models. The models may
capture both the kind of mutations considered such as single nucleotide variants
(SNVs) and structural variants (SVs) and basic questions such as whether those mutations are assumed to be selectively neutral or under selection (Klein 2013). Moreover, this diversity of methods includes variation in the algorithms applied which
include but not only the computational instructions used to find an optimal tree or
trees. The variety of phylogeny methods and tools such as tumor evolutionary trees
have corresponded to a variety of applications and now become central in the results of many studies (Ding, Raphael et al. 2013). Early uses of phylogeny methods
often focused on using evidence of evolutionary selection to separate driver mutations from passenger mutations (Yates, Gerstung et al. 2015), and determining how
these driver mutations associate with progression stages (Urbschat, Rahnenfhrer et al.
2011). Other key later results have emerged organically to address the controversial
question such as whether tumor evolution follows the expectations of classical clonal
3

evolution theory (Bolli, Avet-Loiseau et al. 2014). One conflicting trend among these
studies is their seemingly different conclusions about the evolutionary trajectories of
cancers. The distinctions may be traced to differences in the application of phylogenetics, such as using distinct evolutionary models or looking at distinct marker types
or phylogeny algorithms. For example, the studies concluded that there was little
selection in some tumors looked mostly at CNVs and SNVs, but perhaps there is
selection in those tumors via evolutionary mechanisms that would be apparent only
when looking at other marker types, such as methylation patterns or karyotypes.
Most recent years have witnessed a rapid proliferation of methods for tumor phylogenetics. The approaches can be classified as three categories based on the kind of
phylogeny study for which they are designed.
The first category is the cross-sectional method, which uses data on many tumors
to build trees describing the common progression pathways which seek either the most
probable tree of the maximum likelihood. Compared with the earlier approaches, such
models are better at handling high mutation rates, uncertainty and noisy data in tree
inferences, but can be more computationally demanding than parsimony methods.
Beerenwinkel and coworkers introduced an important class of probabilistic model that
enables the joint inference of several possible trees for binary mutation data through
the Mtreemix tool. This approach has become the basis of the newer Rtreemix package (Rahnenfhrer, Beerenwinkel et al. 2005). The cross-sectional method relies on
comparatively faster maximum likelihood techniques (Gerstung, Baudis et al. 2009).
However, more advanced Bayesian models, using variants of Markov chain Monte
Carlo (MCMC) sampling, are statistical techniques for exploring the ranges of evolutionary parameters and possible tree models (Jiao, Vembu et al. 2014). The alternative to such methods are distance-based methods, which use gene sequencing data
to estimate evolutionary distances between samples. The advantage of such methods
4

can handle much larger marker sets at the cost of losing the fine-scale modeling. Desper and the coworkers extended their approaches from RNA expression data, which
is a distance-based analog of parsimony methods based on RNA-Seq data (Desper,
Khan et al. 2004).
The second category is the regional bulk method, which builds trees for single
patients through bulk genomic assays of distinct tumor regions. In recent years, this
method has been not only used to analyze DNA sequencing-derived SNV or CNV
data (Schwarz, Trinh et al. 2014), but also has been used for methylation data
(Brocks, Assenov et al. 2014). A major step forward was the recognition that one
could produce phylogenies for single patient, initially through sampling multiple regions or tumor sites. One treats each site sequenced as if it was a species and infers
a tree connecting those species. The earliest such tools used data types that predate
NGS, such as large-scale CNVs used by TuMult, a parsimony-based combinatorial
algorithm (Letouz, Allory et al. 2010). Similar ideas have been brought to DNA
sequencing-derived data types. Given the variations in the rates and mechanisms of
SNV versus CNV evolution, some methods have found particular power in combining
different data types (Deshwar, Vembu et al. 2015, El-Kebir, Satas et al. 2016, Jiang,
Qiu et al. 2016). The available methods also cover a range of models and algorithmic
techniques, including various combinatorial (parsimony- like) character-based methods (Hajirasouliha, Mahmoody et al. 2014), probabilistic character-based methods
(Deshwar, Vembu et al. 2015), and distance-based minimum evolution (Schwarz,
Trinh et al. 2014). Sottoriva and the coworkers have proven to be valuable primarily
for the purpose of identifying orders and combinations of recurring driver mutations.
In remembrance, the cross-sectional tumor phylogeny methods are domain-specific
clustering methods. They often use phylogenetics tools based on the assumption
that common evolutionary trajectories can be shared by distinct tumors. Qualitative
5

results may depend considerably on the model used to generate the data and tree
inferences from cross-sectional data can be unreliable in the presence of intra-tumor
heterogeneity (Sprouffske, Pepper et al. 2011), which help motivate the trend towards
phylogenetic studies of single tumors.
The third category is the single-cell method, which builds trees from the cell-tocell variations in single tumor. Single-cell tumor phylogenetics predates single-cell
sequencing (scSeq) through various older methods offering more limited profiling of
single cells. The majority of developed tools for single-cell phylogenetics are still based
on pre-scSeq technologies (Chowdhury, Shackney et al. 2014, Chowdhury, Gertz et
al. 2015, Zhou, Lin et al. 2015). Also, most applications of scSeq phylogenetics to
date have thus relied on tools for phylogenies that have been manually constructed
without an explicit model or algorithm (Anderson, Lutz et al. 2011). Navin et al.
(Navin, Kendall et al. 2011) relied on neighbor joining, which had earlier been used
by Frumkin et al. (Frumkin, Wasserstrom et al. 2008) with microsatellite data, to
infer phylogenies from scSeq-derived CNVs. Neighbor joining was also used by Xu et
al. (Xu, Hou et al. 2012) for application to renal cancers and by Wang et al. (Wang,
Waters et al. 2014) for the largest scSeq study of tumor evolution.
Most studies of tumor phylogenetics to date have adapted standard algorithms
that were developed for species phylogenetics. For example, Huelsenbeck and the
coworkers proposed the various maximum likelihood or Bayesian probabilistic inference methods to study species phylogenetics (Huelsenbeck, Ronquist et al. 2001).
Only recently, some new phylogeny algorithms we developed to deal with the peculiarities of tumor (Chowdhury, Shackney et al. 2013). Nik-Zainal and colleagues
(Nik-Zainal, Alexandrov et al. 2012) have provided an in-depth whole-genome sequencing analysis of 21 breast cancers and conclude that the proliferation and eventual outgrowth of the subclone, precipitating mammographic detection, must have
6

been a rate-limiting event because of the vast number of expression present in subclones within branches of the phylogenetic tree differ from the common somatic events
present in all tumor cells.

1.3

Methods to infer temporal order of alterations

Methods have been developed to infer temporal order of alterations in tumor evolution. The previous methods include the oncogenetic tree (oncotree) approach (Desper,
Jiang et al. 1999), the linear model (Desper, Jiang et al. 1999), various Bayesian
graphical approaches (Hjelm, Hglund et al. 2006), and some clustering-based methods (Hglund, Frigyesi et al. 2005). Vogelstein and the coworkers proposed the linear
model assuming that there exists a single most likely order of mutations and that all
of these mutations arise in sequential order based upon the seminal work in delineating the temporal sequence of events in colorectal cancer (Fearon and Vogelstein
1990).
The oncogenetic tree approach provides a tree structure to the temporal sequence
of mutations and allow for diverging temporal orderings of events (Desper, Jiang et
al. 1999). In probabilistic oncotrees, the tree structure represents the probabilities
of accumulating further mutations along with divergent temporal sequences (Desper,
Jiang et al. 1999).
An alternative distance-based oncotree approach proposed by Desper involves
generating a phylogenetic tree overall events using a distance measure between mutational events (Desper, Jiang et al. 2000). Notably, the mixture tree model can
predict that every mutation arises independently, accounting for random mutations
that arise but are not involved in any temporal order of events. Beerenwinkel and the
coworkers used an expectation maximization algorithm to determine the most likely
tree mixture to fit the data (Beerenwinkel, Rahnenfhrer et al. 2005). However, one
7

acknowledged disadvantage of tree-based methods is that the tree structure precludes
the possibility of converging evolutionary paths that occur when multiple alterations
result in the same phenotypic effect (Beerenwinkel, Rahnenfhrer et al. 2005).
Additionally, there is the strict ordering of events which tree-based models impose.
If an event occurs in a leaf of the tree, then it is necessarily preceded by all events
between the root and the leaf and of the tree. Bayesian graphical methods include
converging evolutionary paths by allowing any network structure (Gerstung, Baudis
et al. 2009). However, the cost of additional computation necessary is also applied
to search the expanded multi-dimensional result space. Juliana and the coworkers
described a linear computational approach, called Retracing the Evolutionary Steps
in Cancer (RESIC), to determine the temporal order of genetic alterations during
tumorigenesis at the fully transformed stage (Fearon and Vogelstein 1990). This approach determines the temporal order of specific genetic events for primary tumor
types for which cross-sectional genomic data is available. RESIC can be used to
resolve the relative order of genetic events with respect to other alterations of interest. But this method cant be used to identify the time of emergence of events
relative to phenotypes such as malignancy or metastasis in the absence of further
data. In the RESIC model, different approaches were adopted to consider the evolutionary dynamics of mutation accumulation within a population of patients. Each
patient harbors a collection of self-renewing cells that are at risk of accumulating the
alterations leading to cancer (Moran 1962).
Ding and colleagues showed that the metastasis may derive from a low-frequency
subclone within the primary through the analysis of structural variations and allelic
frequencies in primary basal breast cancer and brain metastasis from the same patient
(Ding, Ellis et al. 2010). The team noted a wide range of allelic variant frequencies in
the primary tumor but with less divergent mutational frequencies at the metastatic
8

site, suggesting a process analogous to evolutionary bottlenecking through subclonal
selection during the metastatic process (Ding, Ellis et al. 2010). Conceivably, following subclonal selection and the restriction of the bottlenecking, generation of tumor
chromosomal instability (CIN) provides a route to rapidly initiate a further expansion
in tumor heterogeneity.
Specific genetic alterations may not necessary for malignant transformation for
most of the cancer study. In most situation, certain oncogenic phenotypes must be
achieved through the accumulation of a number of alternative mutations (Weinberg
and Hanahan 2000, Colotta, Allavena et al. 2009, Luo, Solimini et al. 2009, Negrini,
Gorgoulis et al. 2010, Hanahan and Weinberg 2011, Cheng, Beroukhim et al. 2012).
Including pathway information may alter the order in which genetic events arise during tumor progression may be altered when including pathway information. Therefore, it is more meaningful to studying temporal order of alterations during cancer
progress at the pathway level. There has been a growing interest to develop methods
to perform temporal order analysis at the pathway level (Gerstung, Eriksson et al.
2011, Cheng, Beroukhim et al. 2012, Raphael and Vandin 2015, Cristea, Kuipers et
al. 2017. Cheng extended RESIC method to incorporate both pathway-based phenotypic changes and the subtype-driven context to determine how the temporal order
of events differs when pathway and subtype information is included (Cheng, 2012).
A major limitation of current methods when including pathway information is that
all alterations are treated equally. However, in most cases, many non-synonymous
alterations do not contribute to cancer progression. Wang proposed PATOPA, a
probabilistic method to incorporate the functional annotation of each mutation and
put more weight on mutations that are likely to be functional when characterizing
the temporal order of mutations at the pathway level (Wang, 2019).
Tumor evolution provides a necessary substrate for Darwinian selection during
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metastatic outgrowth and therapeutic resistance. Subclonal selection and transient
bottlenecking that have been shown to occur during these processes provide a tool to
develop a potential therapeutic opportunity, if this phylogenetic information behind
the tumor evolution can be deciphered. Developing minimally invasive approaches to
monitor tumor subclonal dynamics will be critical for exacerbating subclonal selection and genomic instability. Drawing parallels in cancer with examples of convergent
evolution in ecology proves that it is quite necessary to consider tumor growth within
population genetics and tumor evolutionary models. Gatenby and the coworkers
(Gatenby, Gillies et al. 2011) proposed that such convergent evolutionary events prioritize research on the ecologic tumor niche as the selection force (and in some cases
the driver itself of genomic instability) for genetic adaptation. The repertoire of actionable mutations in the tumor trunk may be expanded by the continued distinction
between branch events and trunk albeit in smaller and smaller patient cohorts.
Novel combinatorial therapeutic strategies may be envisaged to short-circuit future tumor evolutionary networks by illuminating common branched events that may
predispose to therapeutic failure through subclonal outgrowth. Faced with a restricted number of drugs active against defined actionable mutations within individual
tumors, ITH (intratumor genetic heterogeneity) may present profound practical regulatory challenges when considering such drug combinatorial approaches (Gatenby,
Gillies et al. 2011).

1.4

Pathway analysis based on gene expression data

For the past decade, RNA-Seq sequencing techniques have transformed biological
research by enabling comprehensive monitoring of a biological system. Recent technological advances, especially on RNA-seq, have empowered researchers to examine
the cancer genome at unprecedented throughput and resolution. As more and more
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the new technology used, analysis of high-throughput data of RNA-Seq sequencing
typically yields a list of expressed genes or proteins (Khatri, Sirota et al. 2012). RNASeq provides a simple and cost-effective way to profile specific nucleic acid molecules
in a complex mixture. RNA-seq technology has some advantages over the microarrays. RNA-Seq offers improved specificity, so it’s better at detecting transcripts, and
specifically isoforms, than microarrays. It’s also more sensitive in detecting differential expression and offers increased dynamic range, such as the high level of data
reproducibility through flow-cells and lanes, which reduces the number of technical
replicates for the experiments [5]. RNA-Seq sequencing has provided an unprecedented opportunity for using statistical and computational methods to study tumor
evolution.
Measuring all gene expression changes involved in a comparison of two phenotypes has been available for about 15-20 years now with the emerging of biological
techniques. However, the understanding of the underlying biological phenomena still
constitutes a formidable challenge for the human being in spite of having these amazing competencies that were once seen as impossible(Marit, 2009).
Biological pathway-based analysis is a corresponding approach to single-point
analyses. Wikipedia defines a biological pathway asa biological pathway is a series
of interactions among molecules in a cell that leads to a certain product or a change
in a cell. This is a pretty good definition with the goal of identifing the underlying
biological processes and mechanisms through leverage existing knowledge about the
given organism.
A pathway is essentially a description ofphenomenaor mechanisms and usually
described by a graph that contains nodes and edges. There are several types of
pathways such as signaling and metabolic. A pathway is meant to describe certain
phenomena, dependencies and interactions. In essence, pathways are usually meant to
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be models designating the interactions of genes, proteins, or metabolites within cells,
tissues, or organisms, rather than simple lists of genes. There are some well-known
pathway databases including but not limited to KEGG, Reactome, Biocarta, etc.
Generally, these data sets can be used to test whether a set of genes from a biological
pathway are associated with a disease trait of interest. Pathway analysis has become
the ideal approach to gaining insight into the underlying biology of differentially
expressed genes and proteins, as it reduces complexity and increases explanatory
power(Subramanian, 2005).
When obtaining a list of genes that are differentially expressed (DE) between the
two phenotypes of interest, the significance of each pathway is measured by calculating
the probability that the observed number of DE genes in a given pathway were simply
observed by chance. These approaches are Over-Representation Analysis (ORA). The
first generation ORA rely on a pre-defined threshold, which is used to determine a
list of DE genes. The significance of each pathway is then evaluated based on the
degree to which the pathway is enriched in such DE genes. A pathway that contains
significantly more than expected DE genes will more likely to be truly related to the
given condition. This approach depends heavily on the criteria used to select the DE
genes such as the statistical tests and thresholds used.
A second generation of ORA methods was designed to eliminate the reliance on the
gene selection criteria by taking all gene expression values into consideration. These
methods are also known as Functional Class Scoring methods (FCS)( Marit,2009).
The assumption behind these methods is that small but corresponding changes in sets
of functionally related genes may also be significant, as well as the genes that have
large expression changes. Gene Set Enrichment Analysis (GSEA) represents one of the
first approaches of this type developed to identify gene sets from gene expression data
that are related to phenotypes of interest (Subramanian, 2005). Some of the popu12

lar of approaches include Catmap (Thomas, 2004), GlobalTest (Jelle,2004), sigPathway (Lu, 2008), GSA (Bradley,2007), SAFE (William ,2005), PADOG (Adi,2006),
Category (Zhen,2007), PCOT2 (Sek,2007), FunCluster (Corneliu, 2006) SAM-GS
(Irina,2007), etc.
These expression measurements have been used only to rank the genes (FCS), or
to recognize differentially expressed genes (ORA), rather than estimate the impact of
such changes on specific pathways. Thus, ORA techniques will not differentiate between a situation in which the same genes are changing by many orders of magnitude
(e.g. 100-fold) and the situation in which a subset of genes is differentially expressed
just above the detection threshold (e.g. 2-fold). Similarly, FCS techniques can provide the same rankings for entire ranges of expression values under the condition that
the correlations between the genes and the phenotypes remain similar. Examining
this type of information from the levels of a pathway and system context would be
extremely meaningful from a biological perspective.
A substantial amount of information about the biological processes described by
these pathways has been discarded when considering pathways as simple unordered
and unstructured collection of genes. In essence, all the interactions and dependencies
between genes that are meant to capture and describe the biological phenomena
involved are completely disregarded.
Topology-based (TB) methods have been developed to include all this additional
information in the analysis. Besides gene expression changes, these methods also
take into consideration the various positions and roles of all genes on each pathway, in addition to all known signals and interactions between genes. This category of approaches has been developed include the Impact Analysis (Sorin,2007) ,
Pathway-Express (Sorin,2007), SPIA (Adi,2009), ROntoTools (Calin, 2012) BLMA
(Tin, 2016), as well as others (NetGSA (Ali,2004), TopoGSA (Enrico,2009), Topolo13

gyGSA (Maria, 2010), DEGraph (Laurent,2016), PWEA (Jui-Hung,2010), PathOlogist (Greenblum,2011), GGEA (Ludwig, 2011), cepaGSA (Zuguang, 2012), PathNet
(Bhaskar,21012), etc. The shared characteristic of approaches in this category is that
they use the prior knowledge of topology information of pathways to derive some
gene-level statistic which is subsequently used to calculate a pathway-level statistic
used to rank the pathways.
Here we build a new pathway analysis method to infer the temporal order of
alteration of key cancer pathways during tumor evolution. Current methods are
population-based, inferring the order for a group of patients. To our knowledge, no
method has been developed to infer the order of pathway alteration for an individual
patient. Therefore we developed a statistical method to infer the temporal order of
pathway alterations in tumor evolution for each individual patient based on RNA-seq
data. Based on the constructed evolutionary trees, patient-specific pathway analysis is
performed to identify pathways that are altered in the earlier or later phases of tumor
evolution of that patient. Additionally, our method provides a tool of classifying
patients based on how their tumor evolved and what the order if the key pathways,
which greatly imply the anticipation of tumor progress.

Copyright c Tingting Zhai, 2020.
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Chapter 2 Patient-Specific Phylogenetic analysis of tumor evolution
from RNA-seq Counts

2.1

Introductions

Multiple subclones of tumor cells with distinct genomic and transcriptomic profiles
arise during tumor evolution. Although many bioinformatics methods based on gene
mutation data have been proposed to estimate intra-tumor heterogeneity, there are
limited methods for inferring subclonal structures from gene expression data. Additionally, phylogenetics might prove valuable for making sense of tumor progression
processes since cancer is an evolutionary phenomenon which led to the insight of
computational methods for reconstructing evolutionary processes. Most of current
methods are population-based, inferring evolutionary trajectory for a group of patients. Personalized therapeutic approaches have become more practical for clinical
cancer care. So a method to infer the tumor progression processes based on gene
expression alteration for an individual patient is necessary.
Therefore we developed a new statistical method to reconstruct the evolutionary
history and population frequency of the subclonal lineages of tumor cells in tumor
evolution for each individual patient based on RNA-seq data. Our method uses a
Bayesian nonparametric prior and nested stick-breaking process to allow for evolutional trees of infinite nodes, and to identify cell population frequencies which have the
highest likelihood of generating the observed RNA-seq data. Markov Chain Monte
Carlo method based on slice sampling is incorporated to perform Bayesian inference.
Simulations and real data analysis demonstrate that the proposed method reliably
recover the phylogenetic chain and population frequency of the subclonal lineages of
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tumor cells for the individual patient.

Figure 2.1: Project goal

2.2

Methods and Data Model

Our model employed a nonparametric Bayesian approach for reconstructing intratumor phylogenies from observed gene expression data. A nested Dirichlet process
(tree structured stick breaking process) is used as a prior in order to integrate the
arrangement of clones into a tree and the assignment of genes to clones.

Dirichlet process mixture model
Considering the problem of clustering N objects using a Bayesian infinite mixture
model, Dirichlet process (DP) can be used as a prior to allow an infinite number of
mixture components resulting in what is known as DP mixture model (DPMM).

16

DPMM automatically estimate the number of components from the data therefore
avoiding the limitation of fixing the number of components when setting a prior. The
construction of stick-breaking process provided below shows how to draw samples
from a Dirichlet process (Sethuraman, 1994):

νi ∼ Be(1, α), π1 = ν1 , πi = νi

i−1
X

(1 − νk ), θi ∼ H, G =

k=1

∞
X

π i δθ i

i=1

where G is a draw from a DP with base distribution H and concentration parameter α.
The Stick-breaking process can be view as breaking a stick of unit length at random
locations. The stick-breaking construction provides a flat clustering of objects, and
automatically estimate the number of components from the data (Sethuraman, 1994).

Tree Structured Stick Breaking Process
In 2010, Adams extended the construction of stick-breaking process for hierarchical
clustering by interleaving two stick-breaking processes, which results in a relational
clustering of objects where the clusters are connected to form a rooted tree structure
(Adams, 2010). More importantly, unlike classical hierarchical clustering algorithms,
Adams’s construction allows data to reside in the internal nodes, which is a critical feature we model the association of gene expression alterations with subclonal
lineages.
Borrowing the notations from Adam’s paper, let  = (1 , 2 , ..., K ) denote the
nodes of the tree, where  = ∅ denote the root of the tree. Let || indicate the depth
of node, and let i denote the sequence formed by appending i to . The children
of node  is the set {i : i ∈ 1, 2, ...} and let the ancestors of  be denoted by the
set {0 : 0 ≺ }.
Given tree structured stick breaking process (TSSB) is the interleave of two DP
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mixture models, two beta distribution are applied in TSSB process. ν ∼ Be(1, α(||)
determines the size of a given node’s partition as a function of depth. ψ ∼ Be(1, γ)
determine the branching probabilities (Adams, 2010). The size of the partition associated with each  is

π = ν ϕ

X

ϕ0 (1 − ν0 ), ϕi = ψi

0 ≺

X
i −1

(1 − ψj ), π∅ = ν∅

j=1

The Data Model
Let xi the observed count of gene i from normal sample and ai denotes the expression
rate of gene i from normal sample, which is known as reference expression rate of gene
i. Our model incorporates normalization factor cn to adjust for the sample-by-sample
difference due to experimental variations. We assume a Poisson model for xi :

xi ∼ P oisson(ai cn )

Similarly, denote the observed count of gene i from tumor sample by yi . Let the
fraction of gene i from the variant population by θi , and the log ratio of expression
rate of gene i in variant population versus reference population by ωi . We assume a
Poisson model for yi given θi , ωi :

yi |θi , ωi ∼ P oisson(((1 − φ) ∗ ai + φ ∗ (ai (1 − θi ) + ai eωi θi ))ct )

which is
yi |θi , ωi ∼ P oisson((ai (1 − φθi ) + ai eωi φθi )ct )
which is
yi |θi , ωi ∼ P oisson((1 − φθi + eωi φθi )ai ct )
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In order to adjust for the sample-by-sample difference due to experimental variations, our model incorporates normalization factor ct . Additionally, considering
normal tissue cells exist in most tumor samples, a parameter which is tumor purity
denoted by φ is incorporated in the model.
In the model, we assume each alteration of expression appears only once and
once it appears, it does not revert back to its original state. So we can view it
as a combination of expression rate from variant population and that from variant
population.
Due to biological variation, expression rates among tumor samples or normal
samples are not identical. This problem is well recognized in RNA-seq experiments
(Robinson and Smyth, 2007, Anders and Huber, 2010). A common approach to
address the problem is to consider a Bayesian hierarchical model, where a normal
distribution is used to characterize the variation in the underlying log ration of expression rates between variant population versus reference population.

ω = (ω u , ω d )

where for up-regulated genes ωiu ∼ N (µ1 , σ12 );
and for down-regulated genes ωid ∼ N (µ2 , σ22 )
To sum up, the hierarchical model we consider is as follows:
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Figure 2.2: The hierarchical model

The phylogenetic RNA-seq analysis in tumor sample involves a number of steps,
including normalization factor estimation, differential expression analysis and tumor
purity analysis. Appropriate estimation of tomor purity, normalization factor, log
ration of expression rate, and proportion of variant population can effectively improve
the accuracy of tree structure estimation.

Estimation of normalization factor
RNA-seq count quantification and normalization factor cn and ct calculation are performed using the edgeR package (Robinson, McCarthy, and Smyth 2010). The edgeR
package stores data in a simple list-based data object called a DGEList. This object
can be manipulated like an ordinary list in R. We enter the counts into a DGEList
object. Normalization is performed by using the calcNormFactors function, which
returns the DGEList argument with only the norm.factors changed. The product of
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these factors and the library sizes defines a set of normalization factors, which will
be used in our model. Specifically, there is one normalization factor for each sample
to eliminate composition biases between libraries.

Estimation of tumor purity
For bulk tumor tissue analysis, normal cells in tumor tissue play an important role in
influencing the tumor signal in molecular studies. The ESTIMATE package predicts
the presence of stromal and immune cells in tumor tissue using gene expression data.
We apply ESTIMATE to predict tumor purity φ, which is the percentage of tumor
cells in the tumor tissue. Basically, stromal and immune scores that represent the
presence of stromal and immune cells in tumor tissue were calculated respectively.
In addition, by applying this function which represents the correlation between raw
ESTIMATE score and tumor purity, the percentage of tumor cells in the tumor tissue.

Testing for differential expression
The next step is to test for differential expression between the normal tissues and
tumor tissues. We apply the function exactTest in edgeR package to identifies differential expression based on statistical significance. This analysis found more than
5000 DE genes in most cases. With such a large number of DE genes, it makes sense
to narrow down the list to genes that are more biologically meaningful. A commonly
used approach is to apply logFC cutoffs.

The prior distribution of the log ratio of expression rate
We consider the the log ratio of expression rate for down-regulated genes and upregulated genes follows the Gaussian mixture. The GaussianMixtures in sBIC package
can be used to cluster genes. The mean value of the first cluster with the largest log
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ratio of expression rate was applied to be the initial value of the mean of normal
distribution in our model.
Similarly, the conditional posterior distribution of ωiu given θi is

p(ωiu |yi , xi , θi ) ∝ P oisson(ai ct (1 − φθi + eωi φθi )) × N (µ1 , σ12 )

The conditional posterior distribution of ωid given θi is

p(ωid |yi , xi , θi ) ∝ P oisson(ai ct (1 − φθi + eωi φθi )) × N (µ2 , σ22 )

The prior distribution of proportion of variant population of each gene
θi ∼ G, G ∼ T SSB(α, γ, H)
The prior distribution H is Unif(0,1) for the root node and Unif(0, θpar() −

P

ω∈S() θω )

for any other node , where par() denotes the parent node of 

Inference via Markov Chain Monto Carlo
The tree structure and the variant population frequencies are inferred using Markov
chain Monte Carlo sampling. In particular, we use Gibbs sampling to generate posterior samples of the variant population frequencies. Each iteration of the Gibbs
sampler involves multiple subsampling procedures: sampling tree structure, sampling
log ration of expression rate µ, sampling stick lengths, sampling stick-breaking hyperparameters α, γ and λ, sampling the variant population frequencies, sampling ωi
given θ, Sampling stick lengths ν and ψi given the current sticks and assignment
of nodes to data, Sampling stick-breaking hyperparameters α0 , γ and λ given all of
sticks. In the sampling tree structure process, which includes sampling cluster assignment, assign node for each gene, and remove empty nodes.
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A two-step procedure for clonal inference of RNA seq data
The first step is to select genes that are used to build the phylogenetic tree. We select
differentially expressed down-regulated genes as high-confidence genes to be used to
determine the tree structure. Briefly, we use our algorithm described previously to
infer the tree structure and clonal proportion for just down-regulated genes.
The second step is to determine the additional differential expressed genes. Additional up-regulated differential expressed genes will be added into the tree structure
one by one. Given θi predicted based on down-regulated genes and νiu estimated from
the Gaussian mixture estimation, we infer θi for the each up-regulated differential expressed gene.

2.3

Simulations

Simulation settings
We performed comprehensive simulation studies to evaluate the performance of our
method. To evaluate whether our method can truly recover the true tree structure
under realistic scenarios encountered in RNA-seq experiments, data were generated
based on the above model using parameters estimated from the real datasets which
are downloaded from TCGA. The expression for each gene is obtained by taking the
mean expression value of this gene in 26 normal colon tissue. We considered the pure
tumor samples, which means the tumor purity parameter is 1 and the normalized
factor is 1. For the log ratio of expression rate µ, we considered using a normal
distribution with distribution parameters calculated from real data. Explicitly, we
set µ1 for up-regulated genes is 2, and µ2 for down-regulated genes is -2.
We simulated read data from a chain phylogeny with population frequencies 1,
0.8, 0.55 and 0.35. By the sum rule, these frequencies are only consistent with
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a chain phylogeny. To explore the effect of the number of genes in each sample,
we generated two groups of data: (1) Expressions of 48 genes were generated from
P oisson((1 − φθi + eωi φθi )ai ct ). We denoted this as an initial simulation setting
(Figure 2.3). (2) Expressions of 480 genes were generated. We considered this as a
secondary simulation setting (Figure 2.10).
For both simulation settings, the normalization parameters ct and φ were set to
be 1, respectively. In our simulations, we considered half of the genes as up-regulated
gene which are expressed with the log fold change randomly generated from a normal
distribution N (2, 0.3), while the rest of the genes are down-regulated genes which
expressed with the log fold change randomly generated from a normal distribution N
(-2, 0.3).
We first present the results under the initial simulation setting for 48 genes. The
results under the secondary simulation setting for 480 genes are provided later.

Simulation results under initial simulation setting

Figure 2.3: True linear phylogenetic tree from a single sample. The labels of the
nodes are variant population frequencies of its corresponding genes and proportions
of its corresponding subclone of the tumor sample.

As we discussed, in the simulation setting, the normalization parameters ct and
the tumor purity φ were set to be 1. So we only need to estimate the parameter
corresponding to log ratio of expression rate. Figure 2.4 shows the log fold change of
the down-regulated genes in the initial simulation. The fold change of the 24 genes
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is from -0.2 to -3.0.

Figure 2.4: Log fold change of the down-regulated genes in one simulated sample in
initial simulation. The colors of the dots matched with the colors of the nodes in the
true phylogenetic tree in Figure 2.3.

With the paired of simulated RNA-seq data available, firstly the Gaussian mixture
estimation was used to estimate the mean and standard deviation of the distribution
of the log fold change. Basically, the GaussianMixtures in sBIC package can be
used to cluster genes. When clustering the 24 down-regulated genes based on its fold
change which is shown in Figure 2.4, the 24 down-regulated genes are more likely to be
clustered to 4 groups. However,most of the estimated clusters from GaussianMixtures
across 100 simulations are 1-3, which is shown in Figure 2.5. The estimated number
of clusters is less than the true value.
The mean value of the cluster with the largest log ratio of expression rate was
applied to be initial value of the mean of normal distribution in our model. Figure
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Figure 2.5: The estimated number of clusters from GaussianMixture across 100 simulations for down-regulated genes (left). The mean value of the cluster with largest
log ratio of expression rate (right).

2.5 shows that only around half of the 100 simulations the estimated value is near
-2.0 which is the initial setting value. Although GaussianMixtures did not provide a
good estimation because of the small number of genes in the simulation setting, the
mean µ of the distribution of the log fold change is only used as the initial value of
the MCMC process. Similarly, Figure 2.6-2.7 shows the statistics for 24 up-regulated
genes in the first simulation setting.
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Figure 2.6: The log fold change of the up-regulated genes in one simulated sample in
initial simulation. The colors of the dots matched with the colors of the nodes in the
true phylogenetic tree in Figure 2.3.

Same to down-regulated, the Gaussian mixuture estimation was used to estimate
the mean and standard deviation of the distribution of the log fold change. Figure
2.6-2.7 shows the statistics for 24 up-regulated genes in the first simulation setting.
Compared to down-regulated genes, the Gaussian mixuture estimation is more close
to the true value. Most of the estimated clusters from GaussianMixtures across 100
simulations is 4, which is shown in Figure 2.7. The mean value of the cluster with
the largest log ratio of expression rate was applied to be initial value of the mean
of normal distribution for up-regulated genes as well in our model. most of the 100
simulations the estimated value is near 2.0 which is the initial setting value.
We then evaluated whether our method can truly recover the proposed tree structure. Figure 2.8 shows an example of estimated phylogenetic tree. Finally, after
summarizing all the phylogenetic trees generated for the 100 simulated samples, 29
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Figure 2.7: The estimated number of clusters from GaussianMixture across 100 simulation from up-regulated genes (left). The mean value of the cluster with the largest
log ratio of expression rate (right).

out of 100 trees matched the true tree structure.

Figure 2.8: An example of estimated linear phylogenetic tree from a single sample.
The labels of the nodes are variant population frequencies of its corresponding genes
and proportions of its corresponding subclone of the tumor sample.

We then assessed the estimation of proportion of each subclone. Figure 2.9 shows
the estimated proportion of each subclone using our method. Our method provides
accurate estimation of the proportion of each subclone for both up-regulated genes
and down-regulated genes. Specifically, the estimator for down-regulated genes is
better than those for up-regulated genes.
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Figure 2.9: Histogram of the estimated proportion of 48 genes. The colors of the dots
matched with the colors of the nodes in the true phylogenetic tree. G1-G6, G13-G18,
G25-G30, G37-G42 are down-regulated genes, while other genes are down-regulated
genes.
Simulation results under second simulation setting

Figure 2.10: True linear phylogenetic tree from a single sample in simulation 2. The
labels of the nodes are variant population frequencies of its corresponding genes and
proportions of its corresponding subclone of the tumor sample.

To explore the effect of the number of genes in each sample, we considered a
simulation setting with 480 genes. The other simulation settings remained the same.
Similarly, the GaussianMixtures in sBIC package were used to estimate the mean
and standard error of the normal distribution of log ration of expression rate. The
fold change of the 480 simulated genes is shown in Figure 2.11. It indicated the 240
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Figure 2.11: The log fold change of the down-regulated genes for one sample in
simulation 2.

Figure 2.12: The estimated number of clusters from GaussianMixture across 100
simulation from down-regulated genes (left). The mean value of the cluster with the
largest log ratio of expression rate (right).

down-regulated genes should be clustered into 4 groups. Different colors were applied
to distinguish genes with different setting of node proportion. The colors of the dots
matched with the colors of the nodes in the true phylogenetic tree in Figure 2.3.
Figure 2.12 shows the number of clusters and the mean of the normal distribution
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estimated from GaussianMixtures across 100 simulations. Though most of the 100
simulated samples were clustered into 3 groups instead of the true value which is
4, we still get a close estimation for the mean of the log ratio of expression rate.
Additionally, as the number of genes in each sample increased to 480, the estimated
µ is more reliable.
Figure 2.13 and Figure 2.14 show the result for up-regulated genes in the second
simulation setting. Similarly, in most cases of 240 up-regulated genes have been
clustered into 3 groups, and the mean of the normal distribution estimated (µu ) from
GaussianMixtures across 100 simulations is very closed to the true value.

Figure 2.13: The log fold change of the up-regulated genes for one sample in simulation 2.
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Figure 2.14: The estimated number of clusters from GaussianMixture across 100
simulation from up-regulated genes (left). The mean value of the cluster with the
largest log ratio of expression rate (right).

We assessed the estimation of the proportion of each subclone. Figure 2.15 shows
the estimated the proportion of each subclone using our method. By increasing the
number of genes in each sample, we obtained a more accurate estimation for both
up-regulated genes and down-regulated genes.

Figure 2.15: Histogram of the estimated proportion of 480 genes in simulation 2.
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Table 2.1: Comparison of the proportion for 480 genes in simulation 2. G1-G60,
G121-G180, G241-G300, G361-G420 are down-regulated genes, while other genes are
up-regulated genes.
Genes
G1-G60
G61-G120
G121-G180
G181-G240
G241-G300
G301-G360
G301-G360
G361-G420

Bias
0.0215
0.0509
-0.0027
0.0804
0.0086
0.0759
-0.0037
-0.0440

SE
0.0017
0.0013
0.0015
0.0020
0.0011
0.0017
0.0003
0.0011

The percentage of trees matched the true tree structure has been summarized.
Figure 2.16 shows all the 6 types of the phylogenetic tree when analyzing the 100
simulated sample. 80 out of 100 trees matched the true tree structure, which is a
linear phylogenetic tree with four nodes.

2.4

Real data analysis

We applied our method to 435 colon tumor sample from The Cancer Genome Atlas
(TCGA) to identify tumor subclones. We should estimate all of the six parameters
cn , φ, µ1 , σ12 , µ2 , σ22 before applying our method to generate tree structure.
Estimation of normalization factor and tumor purity
We apply edgeR estimate normalization factor ct and tumor purity φ estimation was
performed based on transcriptional profile from RNA-seq using ESTIMATE. Figure
2.17 shows the histogram of each parameter across all tumor samples. Tumor purities
were more than 80 % for the majority of the samples and the variation between
regional samples was not high.
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Figure 2.16: Summary of all estimated phylogenetic trees for simulation 2.

The prior of the log ration of expression rate
Figure 2.18 and Figure 2.19 are the histograms of parameter across all tumor samples
generated from GaussianMixture function for down-regulated genes and up-regulated
genes respectively. The number of clusters was 3 or 4 for majority of the samples.
The mean of log ratio of expression rate for down-regulated genes is around -2, while
that for up-regulated genes is around 2, which matched our simulation setting.
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Figure 2.17: Histogram of normalization factor and tumor purity across all colon
tumors.
With all the input parameters available, we applied our method to generate a
phylogenetic tree for each individual colon tumor. Additionally, we apply two kinds
of normal samples. One is using paired normal tissue which is the adjacent normal
tissue from the sample patient. The second is using unpaired normal tissue which
is to download a gene expression database of Normal tissue from a public resource,
which is The Genotype-Tissue Expression (GTEx). GTEx project is an ongoing
effort to build a comprehensive resource to study tissue-specific gene expression and
regulation. Samples from 54 non-diseased tissue sites across nearly 1000 individuals
were collected, primarily including WGS, WES, and RNA-Seq.
For methods comparison, we considered Phylosub (Brumbaugh et al., 2011), which
is an on-line application to perform phylogenetic analysis for gene mutation data. We
considered the options in Phylosub with their default settings in our analysis.
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Figure 2.18: The estimated number of clusters from GaussianMixture across all colon
tumors for down-regulated genes (left). The mean value of the cluster with the largest
log ratio of expression rate (right).

Figure 2.19: The estimated number of clusters from GaussianMixture all colon tumors
for up-regulated genes (left). The mean value of the cluster with the largest log ratio
of expression rate (right).

Phylogenetic trees comparison
Here we compare multiple phylogenetic trees from same individual tumor which are
generated based on RNA seq with adjacent normal tissue with the trees generated
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based on SNVs.

Figure 2.20: Phylogenetic trees for RNA-Seq (top panel) and SNVs (bottom panel)
of Pt. A6.2680.

The results for patient Pt. A6.2680 is shown in Figure 2.20. The phylogenetic
tree for RNA-Seq is very consistent with the tree structure based on gene mutation
data from the same patient. Additionally, the proportion of the corresponding nodes
in the two trees are very close. This phenomenon occurred in some patients, for
example, Pt. 3489 (Figure 2.21) and Pt. 3660 (Figure 2.22).
However, there exists some patients whose two tree structures based on RNA-Seq
and SNVs are not consistent. For example, there are 3 subclones in the tree structure
generated based on RNA-seq for Pt. 2675, which the tree structure generated based
on SNVs for the same patient has 4 subclones, and the proportions of the nodes do
not match (Figure 2.23). Similar phenomenon occurred in Pt 2685 (Figure 2.24).

Copyright c Tingting Zhai, 2020.
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Figure 2.21: Phylogenetic trees for RNA-Seq (top panel) and SNVs (bottom panel)
of Pt. AA.3489.

Figure 2.22: Phylogenetic trees for RNA-Seq (top panel) and SNVs (bottom panel)
of Pt. AA.3660.
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Figure 2.23: Phylogenetic trees for RNA-Seq (top panel) and SNVs (bottom panel)
of Pt. A6.2675.

Figure 2.24: Phylogenetic trees for RNA-Seq (top panel) and SNVs (bottom panel)
of Pt. A6.2685.
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Chapter 3 Patient-Specific pathway analysis of tumor evolution from
RNA-seq Counts

3.1

Introduction

Carcinogenesis is a complex process which involves a complicated evolution process
in a number of key biological pathways and processes. A better understanding of the
temporal order of alteration of key cancer pathways during tumor evolution is very
important to study the biological mechanism of cancer development and to inform new
therapeutic targets. Current methods are population-based, inferring the order for a
group of patients. To our knowledge, no method has been developed to infer the order
of pathway alteration for an individual patient. Therefore we developed a statistical
method to infer the temporal order of pathway alterations in tumor evolution for each
individual patient based on RNA-Seq data. Based on the constructed evolutionary
trees, a patient-specific pathway analysis is performed to identify enriched pathways
that are altered in the earlier and later phases of tumor evolution of that patient.
Real data analysis demonstrates that the proposed method can infer the temporal
order of pathway alterations for a variety of different cancer types.
In this section, we make an extension to consider the temporal order at the pathway level instead of the gene level. We focuses on pathway specific differences in gene
expression patterns across subclones in bulk tumor tissue. Extension of RNA-seq
phylogenetic analysis to pathway analysis allows for the identification of gene expression patterns in different tumor subclones. Such patterns might have arisen due to
factors related to tumor evolution. We still used publicly accessible RNA-seq data
available for normal and tumor tissue.
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The real RNASeq dataset from The Cancer Genome Atlas (TCGA) colon adenocarcinoma (COAD) data was used to evaluate the performance of our pathway
analysis approach. For some cancer types, the temporal order of pathways has been
well studied. For example, colorectal cancer is frequently initiated by altered gene expression that affects the Wnt signaling pathway, and then progress upon subsequent
mutations in genes involved in MAPK, PI3K, TGF-beta, and p53 signaling pathways
(Kuipers, 2015). So firstly, around four hundred colon tumors were analyzed to validate our method. However, for many other cancer types, temporal orders of pathway
alterations are still largely unknown. So we also applied our method to the breast
cancer RNA-seq datasets.

3.2

The method and data model

Identification of significantly altered pathways
An overview of this method is provided in the figures below. We start from the
profiles of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (Kanehisa,
1997 and 2000) associated with a cohort of patients at various stages of a certain
type of cancer. The temporal order analysis at the pathway level instead of the
individual gene level was performed. Two different methods were used for identifying
significantly altered pathways.
Firstly, we test whether a larger number of genes in a certain pathway are dominants in a node of the tree structure obtained from phylogenetic analysis in chapter
2. We can view it as throwing pathway into the tree structure, instead of grouping
genes into each node, compared with the idea in section two. Specifically, Fisher
exact test was performed to test the alteration of each specific pathway across the
clonal lineages. Then we use the probability matrix P to estimate the ranking of
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functional altered pathway, where the (i,j) element of the matrix, pi,j , indicates the
probability of the ith pathway alteration occurring in the jth subclone.

Table 3.1: Example of contingency table for pathway and subclones

Pathway1

Yes
No

Subclone 1
Yes
n1
n3
Genes altered
in subclone1

No
n2
Genes in pathway1
n4
Genes NOT in pathway1
Genes NOT altered
in subclone1

Before elaborating this method in subsequent subsections, we use the following
example to illustrate the idea of building probability matrix P. Consider an example
of determining the temporal order of pathways A and B in Figure 1. Notice that all
genes in pathway A altered in subclone 1, while all genes in pathway B altered in
subclone 2, which occurs after subclone 1. So this would suggest that pathway A is
likely to be altered before pathway B during carcinogenesis. However, in most cases,
the expression of genes altered at multiple subclones. As shown in Figure 1, genes C1
and C2 altered in subclone 3, while there exists another gene (C3 ) altered in different
subclone (subclone 4). Therefore, a pathway is considered as being functionally
altered if a relatively large number of genes in this pathway have occurred. As
shown in Figure 3.1, for each pathway, we generate a contingency table showing the
distribution of one pathway in rows and subclone in columns, used to study the
association between the two variables. P-value for the association test was obtained
using the Fisher exact test. With this probability matrix available, estimating the
temporal order of functional altered pathways for specific patient is feasible.
Given the p-value matrix (pathway by subclone), we define the node of a certain
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Figure 3.1: Probability matrix construction for each tumor in method 1.

pathway as the node with a p-value less than 0.05. Figure 3.2 provides an overview of
the framework. After the rank of the altered pathway for each tumor was obtained,
this process was applied to all tumors. Building upon this test, we performed pathway
enrichment screening of the nodes of the evolutionary tree structure.
A second method was applied to KEGG pathway genes in order to detect the order
of paired pathways that were affected during tumor evolution. Basically, for every two
pathways, a standard permutation test for genes in these two pathways that randomly
re-signs genes can be used. We propose a test statistic, TP Q , to examine whether a
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Figure 3.2: Generate ranking of pathways across tumors in method 1.

gene pathway P altered before the other pathway Q during tumor evolution.
We use the following example to illustrate the idea of permutation. Consider two
pathways P and Q. Suppose there are 100 genes in each pathway. We took one gene
in each of the two pathways, and denoted them as a pair of genes. So there were
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10000 pairs. A test statistic, TP Q was proposed to examine the number of pairs that
the gene from pathway P altered earlier than the gene from pathway Q.
Permutation was performed as the following steps: 100 genes out of the total
200 genes were randomly sampled as pathway P, while the rest of 100 genes went
to pathway Q. Then TP Q was calculated. After sampling genes and calculating TP Q
score a larger number of times, the distribution of TP Q by random chance was generated. Building upon this test, we performed pathway order analysis for each paired
of pathways. A p-value cutoff (0.05) was applied in order to assess the significant
pathway identification for each tumor.

Detecting repeated cancer evolution across multiple tumors
Inferring repeated evolution trajectories is valuable for the anticipation of cancer
progression. With multiple tumor samples for a certain cancer type available, we
can infer the temporal order of pathway and repeated evolutionary trajectories in
subgroups of patients, and further analyze the association between the identified evolutionary trajectories with the clinical outcome of the subgroups of patients. Varieties
of cluster methods can be applied to cluster the patients, like kmeans and hierarchical
method. Specifically, hierarchical method were applied in our real data analysis and
log-rank test was used to test the difference among survival curves.

3.3

Real data analysis

Case study 1: pathway analysis of colon cancer
To assess our method on single samples, we applied it to the real RNA-Seq dataset
from The Cancer Genome Atlas (TCGA) rectal cancer data. For some cancer types,
the temporal order of pathways has been well studied. For example, colorectal can-
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cer is frequently initiated by altered gene expression that affects the Wnt signaling
pathway, and then progress upon subsequent mutations in genes involved in MAPK,
PI3K, TGF-beta, and p53 signaling pathways (Kuipers, 2015).
Firstly 357 colon tumors were analyzed to validate our method. We analyzed 9
pathways which are cell cycle, MAPK signaling pathway, p53 signaling pathway, Wnt
signaling pathway, apoptosis, TGF-beta signaling pathway, VEGF signaling pathway,
adherens junction, PI3K-Akt signaling pathway. We apply edgeR to estimate normalization factor ct , and ESTIMATE is used to predict tumor purity γ. Gaussian
mixuture estimation is used to estimate the initial mean and standard deviation of
the normal distribution of the log fold change.
Given RNA-seq data of each cancer, we conducted analysis through the following
three steps: firstly, we constructed a phylogenetic tree structure from gene level,
then we conducted pathway analysis to obtain the dominant node for each of the 9
pathways in the tree structure. Last but not least, all the individual phylogenetic
trees had been summarized to indicate the overall trade of the tumor evolution for
this specific cancer type.
One of the major advantages of our method is tumor evolution for each individual
patient is able to be generated. In Figure 3.3, the results for two patients are listed.
For patient 2710, both of MAPK signaling pathway and PI3K-Akt signaling pathway
altered before cell cycle. Additionally, the p53 signaling pathway altered in one
branch, while apoptosis altered in the other branch. For patient 2710, PI3K-Akt
signaling pathway altered at the early stage, while TGF-beta signaling pathway, cell
cycle and adherens junction pathway altered at the late stage.
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Figure 3.3: Phylogenetic trees for pt. 2710 (top) and 5662 (bottom) at pathway level.
From up to bottom, the pathways are MAPK signaling pathway, PI3K-Akt signaling pathway, Wnt signaling pathway, TGF-beta signaling pathway, VEGF signaling
pathway, cell cycle, adherens junction, p53 signaling pathway and apoptosis.

Analysis of gene expression alterations of chosen nine signaling pathways in colon
cancer is summarized in Figure 3.4. It shows the depth of the node for the 9 pathways
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in the tree structure. Each red dot represents one colon tumor. Taking MAPK signaling pathway as an example, most of the red dots show MAPK signaling pathway
falls in the root of the tree structure, which means in most of the colon tumor sample,
the genes in MAPK signaling pathway altered at a very early stage of the evolutionary process. Overall, MAPK, PI3K-Akt and Wnt signaling pathway altered at a
relatively early stage, then cancer progress upon subsequent expression alterations in
genes involved in TGF-beta, VEGF signaling and cell cycle, while gene expression
alterations in p53 signaling pathway and apoptosis occurred at relatively late stage.
MAPK signaling and PI3K-Akt signaling pathways are two known important
downstream effector signaling pathways of KRAS signaling (Papke, 2017). KRAS
harbors activating mutations in about 50 % of all colorectal cancer cases(Porru,
Pompili et al. 2018) . Mutated and activated RAS deregulated downstream MAPK
signaling and PI3K-Akt signaling, affecting cell proliferation, metastasis and survival
and driving tumorigenesis (McCormick 2015). Wnt signaling plays important role
in intestinal tissue repair and homeostasis and deregulated Wnt signaling is believed
to be involved in the development of colorectal cancer through decades of research
(Schatoff, Leach et al. 2017). Our method of analyzing gene expression alterations
of chosen nine signaling pathways reveals that MAPK signaling, PI3K-Akt signaling
and Wnt signaling are the top three altered pathways, which agrees with a wealth of
literature evidence, suggesting the robustness of our approach.
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Figure 3.4: Boxplot of the depth of nodes for 9 pathways in colon tumors.

After constructing the phylogenetic tree structure for each tumor, we want to
detect repeated cancer evolution across those multiple tumors. By applying our
method to single sample cohorts, the order of pathways for a single patient was
identified. Given the phylogenetic tree structure of every single tumor, our method
detected repeated evolutionary trajectories in subgroups of patients. The heatmap in
Figure 3.5 shows four clusters. In cluster 2, the MAPK signaling pathway (P1) altered
before the cell cycle (P6) and the apoptosis (P9). In cluster 3, the MAPK signaling
pathway (P1) altered before the VEGF signaling pathway (P5) and the apoptosis
(P9). Our method provides a means of classifying patients on the basis of how their
tumor evolved with the implications for the anticipation of disease progression.
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Figure 3.5: Subgroups identified with order of pathways in colon tumors. P1: MAPK
signaling pathway P2: PI3K-Akt signaling pathway P3: Wnt signaling pathway P4:
TGF-beta signaling pathway P5: VEGF signaling pathway P6: Cell cycle P7: Adherens junction P8: p53 signaling pathway P9: Apoptosis.

Survival analysis highlighted significant differences among different clusters of
colon tumors (Figure 3.6). Cluster 1 showed considerably better survival compared
with cluster 3.
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Figure 3.6: Overall survival analysis among three clusters of colon tumors.

Case study 2: pathway analysis of breast cancer
Breast cancer is one of the most common cancers with greater than 1 million cases.
RNA-seq data from bulk tumor samples were obtained from 865 patients. We analyzed 969 genes in 8 pathways which are estrogen signaling pathway, cell Cycle,
MAPK signaling pathway, p53 signaling pathway, Wnt signaling pathway, homologous, PI3K signaling pathway and notch signaling pathway.
Analysis of gene expression alterations of chosen nine signaling pathways in breast
cancer is summarized in Figure 3.7. Same as Figure 3.4, each red dot represents one
colon tumor. Overall, MAPK, PI3K-Akt signaling pathway altered at a very early
stage, then cancer progress upon subsequent expression alterations in genes involved
in notch, cell cycle, estrogen and p53 signaling pathway, while gene expression alterations in Wnt signaling pathway and homologous occurred at a relatively late stage.
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Figure 3.7: Boxplot of the depth of nodes for 8 pathways in breast tumors.

MAPK signaling, PI3K-Akt signaling, and notch signaling, pathways are the top
three highly changed signaling pathways on the gene expression level. Although
KRAS signaling is aberrantly unregulated in many cancers, the mutation frequency
of KRAS in breast cancer is low (Kim, Suh et al. 2015). Elevated MAPK expression
in human breast cancer was detected compared with surround normal breast tissues
during breast tumorigenesis (Adeyinka, Nui et al. 2002). PIK3CA mutations, PTEN
loss and mutational AKT activation lead to up-regulated PI3K-Akt signaling, suppressing apoptosis, driving cell proliferation and causing trastuzumab resistance in
breast cancer (Berns, Horlings et al. 2007, Mirzoeva, Das et al. 2009). Abnormal
Notch signaling was reported in breast cancer. Many notch signaling pathway components in breast cancer are upregulated, including notch ligands, notch receptors,
and Hes and Hey target genes (Mittal, Subramanyam et al. 2009). On the contrary,

52

the negative Notch signaling regulator Numb is shown to be lost in 50 % of breast
cancer (Pece, Serresi et al. 2004). In summary, our approach successfully teases out
the highly aberrant signaling pathways in breast cancer, and might provide guidance
on which signaling pathways to target for breast cancer management.

Figure 3.8: Subgroups identified with order of pathways. P1: MAPK signaling pathway P2: PI3K-Akt signaling pathway P3: Notch signaling pathway P4: Estrogen
signaling pathway P5: Wnt signaling pathway P6: p53 signaling pathway P7: Cell
cycle P8: Homologous.

Based on pairwise pathway order probabilities, we grouped the breast tumors into
4 clusters. The heatmap in Figure 3.5 shows the identified order of pathways in the
four clusters. In cluster 2, the MAPK signaling pathway (P1), PI3K-Akt signaling
53

pathway (P2), Wnt signaling pathway (P5) and p53 signaling pathway (P6) altered
before Cell cycle (P7) and Homologous recombination (P8). In cluster 3, the MAPK
signaling pathway (P1) altered before estrogen signaling pathway (P4). Our method
provides a means of classifying patients on the basis of how their tumor evolved with
the implications for the anticipation of disease progression.
Survival analysis highlighted significant differences among different clusters of the
patients in Figure 3.9. cluster 1 showed considerably better survival compared with
cluster 2.

Figure 3.9: Overall survival analysis among three clusters of breast tumors.

Copyright c Tingting Zhai, 2020.
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Chapter 4 Multi-Regional Tumor evolution from RNA-seq Counts

4.1

Introductions

In cancer genome studies, a single tumor biopsy specimen is typically used since it
is cost-effective. However, it may represent incompletely the underlying mutational
and transcriptional profiles of tumor biology, while multi-regional biopsies have the
advantage of increased sensitivity for genomic profiling. In this section, we extend our
statistical model in section 2 to multiple samples from the tumor population. These
RNA-seq data from multiple samples of the same tumor were then used to partially
reconstruct the evolutionary history of tumors. Basically, we devolved a method that
automatically infers tumor phylogenies from RNA-seq data measured in multiple
tumor samples. It still uses Bayesian inference, based on Markov Chain Monte Carlo
(MCMC) sampling, to infer a distribution over phylogenies and a Dirichlet process
prior over phylogenies to group genes into major subclonal lineages based on RNAseq data from multiple samples. We model multiple samples from the same cancer
as sharing the same evolutionary history but allow changes in subclonal frequencies
among samples.
On the other hand, multi-regional biopsies are not cost-effective. It’s necessary
to determine if the pooling of different regions is able to represent the tumor sample
at the genomic and transcriptome level. We performed our method to four regional
samples for four cancer types including colon, stomach, kidney and liver cancer. Subsequently, a comparison in mutations and gene expression profiles between multiple
regional biopsies for each tumor was performed. Our analysis revealed a single biopsy
may not be sufficient for detecting subclones at the transcriptome level.
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4.2

Methods and Data Model

Our method to analyze a single tumor can be easily extended for multiple tumor
samples. We allow the tree-structured stick breaking process prior to being shared
across all the samples. Let x, yij denote the observed count of gene i from the normal
sample and tumor sample j ∈ 1, 2, .., S, respectively. ai denotes the expression rate of
gene i from the normal sample. Our model incorporates normalization factor cn and
ctj to adjust for the sample-by-sample difference due to experimental variations for
the normal sample and tumor sample j, respectively. Let θij denote the fraction of
gene i from the variant population for sample j. Additionally, tumor purity for sample
j denoted by φj and the log ratio of expression rate of gene i in variant population
versus reference population by ωi .
We assume a Poisson model for xi and yi given θi , ωi :

xi ∼ P oisson(ai cn )

yij |θij , ωi ∼ P oisson(((1 − φi ) ∗ ai + φi ∗ (ai (1 − θij ) + ai eωi θij ))ctj )
which is
yij |θij , ωi ∼ P oisson((1 − φj θij + eωi φθij )ai ctj )
To sum up, the graphical model is shown in Figure 4.1.

56

Figure 4.1: The hierarchical model

The main technical difference between the single and the multiple sample models
lies in the sampling procedure for variant population frequencies for genes. In the
multiple sample model, with the condition that the clonal evolutionary constraints
described in the previous section are satisfied separately for each tumor sample, we
P
make a global Metropolis-Hastings move based on the distribution Sj=1 p(θij |), where
θi1 , θi2 , ..., θiS is the set of variant population frequencies for all the tumor samples.
Similarly, the phylogenetic RNA-seq analysis in tumor sample involves a number
of steps, including normalization factor estimation, differential expression analysis
and tumor purity analysis. Appropriate estimation of tumor purity, normalization
factor, log ration of expression rate, and proportion of the variant population can
effectively improve the accuracy of tree structure estimation.
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4.3

Simulations

Simulation settings
To evaluate whether our method corresponding to multiple sample from the same
tumor can truly recover the true tree structure, data were generated using parameters
estimated from the real datasets which was downloaded from TCGA. The expression
for each gene is obtained by taking the mean expression value of this gene in 26 normal
colon tissues. We considered the pure tumor samples, which means the tumor purity
parameter is 1 and the normalized factor is 1. For the log ratio of expression rate µ, we
considered using a normal distribution with distribution parameters calculated from
real data. Explicitly, we set µ1 for up-regulated genes is 2, and µ1 for down-regulated
genes is -2. The normalization parameters ct and φ were set to be 1, respectively.
Expressions of 480 genes were generated.
Similar to the simulation setting in section two, we considered half of the genes as
up-regulated gene with log fold change randomly generated from a normal distribution N (2, 0.3), while the rest of the genes are down-regulated genes with the log fold
change randomly generated from a normal distribution N (-2, 0.3). The main difference between the single sample simulation setting and the multiple sample setting is
adding one more sample with variant population 1, 0.85, 0.60, 0.40.

Figure 4.2: True linear phylogenetic tree from single sample. The labels of the nodes
are variant population frequencies of its corresponding genes and proportions of its
corresponding subclone of the tumor sample.
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We first evaluated whether our method can truly recover the proposed tree structure. Figure 4.3 shows an example of an estimated phylogenetic tree. The first line
of the label under the nodes is corresponding to sample one in the simulation setting,
while the second line of the label under the nodes is corresponding to sample two in
the simulation setting.

Figure 4.3: Example of one estimated phylogenetic tree. The labels of the nodes
are variant population frequencies of its corresponding genes and proportions of its
corresponding subclone of the tumor sample.

Figure 4.4: Bar chart of the variant proportions of genes in sample 1

Figure 4.5 and Figure 4.6 show the estimated the proportion of each subclone

59

Table 4.1: Comparison of the proportion for 480 genes in multi-regional simulation
setting. G1-G60, G121-G180, G241-G300, G361-G420 are down-regulated genes,
while other genes are up-regulated genes.
Genes
G1-G60
G61-G120
G121-G180
G181-G240
G241-G300
G301-G360
G301-G360
G361-G420

Sample 1
Bias
SE
0.0188 0.0008
0.0164 0.0008
0.0063 0.0010
0.0238 0.0013
0.0244 0.0009
0.0693 0.0014
-0.0005 0.0001
-0.0093 0.0005

Sample 2
Bias
SE
0.0190 0.0008
0.0157 0.0008
0.0061 0.0010
0.0244 0.0013
0.0232 0.0009
0.0554 0.0014
-0.0003 0.0001
-0.0066 0.0005

using our method for sample one and sample two, respectively. Since we are using
the same setting with the second simulation setting in Chapter 2, the estimated
proportion from those two simulations is compatible.

Figure 4.5: Bar chart of the variant proportions of genes in sample 2.

By comparing the result for sample 1 in table 2.1 and table 4.1, when two samples
are available to interpret certain phylogeny tree, more accurate estimation can be ob-
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tained. Incorporating more samples provides an accurate estimation of the proportion
of each subclone for both up-regulated genes and down-regulated genes.

Figure 4.6: Summary of all estimated phylogenetic trees from multi-regional tumor.

After summarizing all the phylogenetic trees generated for the 100 simulated samples, 84 out of 100 trees matched the true tree structure (Figure 4.6). Since the
information from the two samples is richer to infer the tree structure than a single
sample, we obtain a more accurate estimation.
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4.4

Real data analysis

Four types of cancer including colon, stomach, kidney and liver cancer were used to
evaluate the performance of our proposed method. Je-Gun Joung et al. performed
sequencing of four regional samples and pooled samples for these four cancer types
including hepatocellular carcinoma, stomach adenocarcinoma, renal cell carcinoma,
and colon adenocarcinoma (SRP066596). Each surgical sample for genome analysis
was obtained from four different tumor foci falling with the same distance (Je-Gun
Joung, 2016).

Comparison of subclones based on gene expression
To compare trees from different samples and tumors, we applied our method to gene
expression profiles of the four different tumor foci for each of the four cancer types
mentioned above. Across all RNA-seq data from 20 samples, the expression profile of
17,145 coding genes were obtained, and tumor purities were calculated using published
R package ESTIMATE based on transcriptional profile. Each sample is denoted by
the tumor and a number. For example, The samples from colon cancer are denoted
as C1 , C2 , C3 and C4 .
Figure 4.7 indicates that among the colon samples, all of the four samples have
most of their mass assigned to levels two. Additionally, the first two samples from
the left side have some of their mass assigned to root, though there is no root mass
any more in the C3 and C4 . Overall, the four samples have relatively high similarity.
Among the stomach samples, we find that most of the tumor mass is at the third
level, and only S1 has a considerable proportion of the root mass. Stomach cancer
displays more topological diversity than colon cancer.
Among the liver samples, we find that all of the four samples have most of their
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mass assigned to levels two. Additionally, the first two samples from the left side
have most of their mass assigned to levels three, though the tumor mass in the L4 is
mostly at the fourth level.
Lastly, kidney samples display the highest diversity among the four cancer types.
We find that the first samples from the left side have most of their mass assigned
to level three with light blue node, though the rest three samples have most of their
mass assigned to levels three with a dark blue node. Additionally, K2 and K4 have a
considerable proportion of the root mass.
Overall, colon cancer displays the lowest diversity among the four cancer types,
which matched the conclusion from Je-Gun Joung’s paper. Interestingly, among the
kidney samples, the two nodes in level three (light blue and dark blue) didn’t exist at
the time in one sample, for example, light blue node dominant K1 , while dark blue
node dominant K2 , K3 and K4 .

Comparison of subclones based on mutation profiles
For comparison, we considered Phylosub (Brumbaugh et al., 2011), which is an online
application to perform phylogenetic analysis for gene mutation data. We considered
the options in Phylosub with their default settings in our analysis. Figure 4.8 shows
the phylogenetic tree for colon, stomach kidney and liver cancer.
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Figure 4.7: Mass distribution of colon, stomach, kidney and liver cancer based on
bulk RNA-seq. For each tree, the bars show the proportion of the subclones for all
four samples of the colon tumor and stomach tumor, respectively. The green bars
correspond to the root masses sample from the posterior distribution with highest
likelihood. The blue, red and grey bars correspond to the second, third and fourth
tree levels, respectively.
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Figure 4.8: Mass distribution of colon, stomach, kidney and liver cancer based on
SNVs. For each tree, the bars show the proportion of the subclones for all four samples
of the colon tumor and stomach tumor, respectively. The green bars correspond to the
root masses sample from the posterior distribution with highest likelihood. The blue,
red and grey bars correspond to the second, third and fourth tree levels, respectively.

4.5

Discussion

High-quality human cancer tissue is required in order to obtain the most accurate
results. Because the cost of next-generation sequencing is decreasing and sequencing
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of multi-regional samples could cover a larger number of variants, we need to analyze
multiple samples from a single tumor specimen in order to make sure minor variations
are represented.
Due to tumor heterogeneity, it has been a challenge to understand the actual
distribution of gene expression profiles presented in bulk tumor specimens. We have
deconvolved each regional sample and compared the analytical performance of SNVs
and RNA-seq in multiple regional samples. Our analysis indicated that some subclone compositions were concordant across regions, however, some discrepancies were
observed. For example, in kidney samples it suggests that a single biopsy is not
sufficient to determine individualized cancer therapy. When we compare RNA expression profiles among multiple regions in specific cancer patient, our phylogenetic
result showed that the expression was relatively unstable across multiple regions in
cancers. A single biopsy may not be able to accurately estimate the composition of
subclones in certain tumors.
Although most variances across different regional samples from the same tumor
were due to intratumoral heterogeneity, some variation may also due to technical
problems during the biopsy process. Thus, further studies are required to resolve
technical issues and more caution should be taken when interpreting sequencing results.
There are still some limitations in our method, including sample size and subclone
estimation issues. It is necessary to have more test samples in order to achieve an
accurate assessment. Only two sample simulation and four regional real cancer sample
have been analyzed. Additionally, only one set per tumor type was examined in this
study. To make a more reliable conclusion, this study will be extended in a larger
sample size to better understand and characterize the regional tumor heterogeneity.
In addition, the clonal status estimation will be incorporated with the estimation from
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mutation and copy number profiles with tumors and their matched normal samples.
In conclusion, different phylogenetic tree structures and subclone compositions
generated from mutation and gene expression profiles within a single tumor were
observed in four cancer types, and it may not be sufficient to determine personalized
cancer therapy just based on a single biopsy.

Copyright c Tingting Zhai, 2020.
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Chapter 5 Discussion and further work

5.1

Discussion for project based on bulk RNA-seq data

Our method offers a comprehensive and general framework to characterize RNA-seq
data and to detect subclones in bulk tumor tissue. As a method specifically designed
for RNA seq data, it utilizes a Poisson-based model to fit the discrete nature of the
data and incorporates several parameters in the model to fully adjust for platform
source of variation and tumor purity. By applying our method, the phylogenetic
tree in both of the gene levels and pathway levels for each individual patient can be
preformed. Simulation and real data analyses results show that this new method can
reliably recover the true subclone composition and evolution process.
The choice of normal tissue is a crucial part of the experimental design. It is
expected that the expression in the bulk tumor tissue in the combination of expression
from tumor cells and expression from the normal cell, which is directly obtain from
the normal tissue, that is, the read counts from the normal tissue should not vary
much across samples or replicates and close to the read counts from the normal cell
in bulk tumor sample. In real data analysis, however, this is not always the case. It is
not only because of biological diversity, but also due to the complicated composition
of the tumor tissue. Besides of normal cell and tumor cells, it has been proved that
there are a variety of different immune cells in most of tumor tissue. Therefore, we
recommend checking the variation of expression in normal tissues prior to estimating
the subclones of the tumor composition. Further investigation of tumor composition,
especially the effect of immune cell will be very important.
The present study has also revealed a major challenge we identified, which is
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how to compare evolutionary trees with different numbers of nodes, different tree
structures, and different node labels and compositions. A general distance measure
between trees of tumor evolution is lacking. Ideally, a good tree comparison measure
would combine the overlap between node content with a measure of graph similarity.
Tree comparison would not only be important for comparing evolutionary trajectories
of tumors for distinct types of genomic data, but also for comparing evolutionary
trajectories of tumors in time.

5.2

Future work based on single cell RNA-seq

Recently the single cell RNA sequencing (scRNA-seq) methods have been rapidly
spread and created a large variety of experimental and computational pipelines.
scRNA-seq has enabled gene expression to be studied at an unprecedented resolution. It provides the expression profiles of individual cells. The huge advantage of
this technology is attracting more and more user base for singlecell analysis methods.
Although due to technical limitation and a small amount of material available, it is
not possible so far to obtain complete information for every single RNA expressed
by each cell, most of the gene expression can be identified through gene clustering
analyses.
Furthermore, distinct methods including differential expression (DE) analysis,
clustering of cells, classification of cells and trajectory reconstruction have been developed. The huge advantage of this technology is attracting more and more user
base for singlecell analysis methods.
The nonparametric Bayesian approach we generated for reconstructing intratumor phylogenies based on bulk tissue should be able to be extended to scRNA-seq
with some important modification. Similarly, a nested Dirichlet process (tree structured stick breaking process) is used as a prior. The big difference is that instead of
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integrating the arrangement of genes into a tree, we should assign every single cell to
clones for scRNA-seq analysis.

The Data Model
Let i ∈ 1, ..., M denote the considered gene sites and n ∈ 1, ..., N index the observed
single cell sequences. We denote the gene expression at site i of sequence n by xin ,
which is non-negative count. To assign sequences to clones, each clone has a label.
Following the notation in chapter two, the clone label is defined as  = (1, ..., K),
where k ∈ N for all k ∈ 1, ..., K. Each label is a sequence of natural numbers
indicating the location of the clone in the phylogenetic tree.
To model single-cell expression data, we specify the local probability distributions
p(xn |θ ) and the transition probabilities p(θ |θpa() ). For each clone , the local data
distribution is a Poisson distribution. The parameter θi ∈ R is used to control the
probability of observing a certain log ratio of expression change at locus i. Assuming
independence among loci, we set

xn |θ ∼ P oisson(ai eθ i, )

Here, we assume the gene sites are independent.
For the transition probabilities, we use a mixture of three Laplace distributions
to model the parentchild relation,

p(θ |θpa() , µ, σ, α, β) =

M
X

αi Laplace(µ, σ)+(1−αi −βi )Laplace(0, σ)+βi Laplace(−µ, σ)

i=1

where µ defines the location of a up-regulated and a down-regulated mode, α= {αi }M
i=1
and β= {βi }M
i=1 . Intuitively, the up-regulated mode generates parameters that give a
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high probability of observing up-regulated events, whereas the down-regulated mode
has the opposite effect. The hyperparameter models variation within the modes. The
weights αi , βi and 1 − αi − βi of the three Laplace densities specify the probabilities of
one of the three mode being selected for sampling the child parameter. The Laplace
densities have the effect of pushing the sampled parameters close to the modes µ or
−µ.
Additionally, the root prior is defined as

p(θ0 ) =

N
X

Laplace(0, σ)

i=1

This prior favors clones with normal expression states at all loci as the root.

Challenges
There are markedly differences between RNA-seq and scRNA-seq data. Specifically,
unlike bulk RNA-seq, the majority of the observed expression in scRNA-seq are zeros.
Some of them indicates genes not expressing RNA at the loci. However, in some cases.
it may due to technical issue that genes expressing RNA is not at a sufficient level to
be detected by sequencing technology. What distribution to characterize scRNA-seq
count data should be well studied.
The limitation of this approach has been revealed. Like our method for bulk RNAseq data, scRNA from normal tissue is mandatory in order to apply our method
to generate tumor evolution progression. Additionally, we assume the gene sites
are independent, which might be violated for genetic linkage theory. Most classical
phylogenetics methods shared with this limitation, which can be overcome using
hidden Markov models. An important topic for future research is to develop a method
to incorporate genetic linkage under this situation.
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Another limitation is that there are tens of parameters needed to be updated in
the MCMC inference scheme, which makes MCMC is extremely slow. It is important
to notice that the information obtained from a small number of gene locus may
not sufficient to infer the complete evolutionary history. By increasing the number
of genes can provide more information, as well as leading to MCMC scheme timeconsuming. Therefore, an improved (approximate) inference method should be also
considered.

Copyright c Tingting Zhai, 2020.
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Appendix

Main function in chapter 2
Main function for MCMC
run(fin=’data.txt’,prodfile=’prod.npy’,fout=’./best’,out2=’top_k_trees’,
out3=’clonal_frequencies’,out4=’llh_trace’,out5=’rate_est’,
num_samples=2500,mh_itr=5000,rand_seed=1,normfactor1=1.00,
normfactor2=1.00,purity1=1.00,purity2=1.00,meandn=-2.0,sddn=0.2):
if not os.path.exists(fout):
os.makedirs(fout)
else:
call([’rm’,’-r’,fout])
os.makedirs(fout)

seed(rand_seed)
codes = load_data(fin,prodfile)
#print(codes[])
NTPS = len(codes[0].a) # number of samples / time points
glist = [datum.name for datum in codes]
num_gene = len(codes)

root

= alleles(conc=0.1,ntps=NTPS)

tssb

= TSSB( dp_alpha=dp_alpha, dp_gamma=dp_gamma, alpha_decay=alpha_decay,

root_node=root, data=codes, num_up=num_gene, normfactor1=normfactor1,
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normfactor2=normfactor2,purity1=purity1,purity2=purity2, meandn=meandn
,sddn=sddn)

dp_alpha_traces = zeros((num_samples, 1))
dp_gamma_traces = zeros((num_samples, 1))
alpha_decay_traces = zeros((num_samples, 1))
conc_traces

= zeros((num_samples, 1))

cd_llh_traces
rate_est

= zeros((num_samples, 1))

= zeros((num_samples, num_gene))

intervals = zeros((8))
best_tssb = 0
freq = dict([(g,[] )for g in glist])

print("Starting MCMC run...")
for iter in range(-burnin,num_samples):

tssb.resample_assignments()
times.append(time.time())

# assign node ids
wts,nodes=tssb.get_mixture()
for i,node in enumerate(nodes): node.id=i

mh_acc = metropolis(tssb,mh_itr,mh_std,mh_burnin,NTPS,fin)
tssb.resample_mhypers()
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tssb.resample_hypers()
tssb.resample_sticks()
tssb.resample_stick_orders()

if iter >= 0:
tssb.resample_hypers(dp_alpha=True, alpha_decay=True, dp_gamma=True)
times.append(time.time())

intervals = intervals + diff(array(times))

if iter>=0:
dp_alpha_traces[iter] = tssb.dp_alpha
dp_gamma_traces[iter] = tssb.dp_gamma
alpha_decay_traces[iter] = tssb.alpha_decay
conc_traces[iter]

= root.conc()

cd_llh_traces[iter]
rate_est[iter]

= tssb.complete_data_log_likelihood()

= exp(tssb.rate1)

if iter>=0:
if True or mod(iter, 10) == 0:
(weights, nodes) = tssb.get_mixture()
intervals = zeros((8))

if iter >= 0 and argmax(cd_llh_traces[:iter+1]) == iter:
if iter >= 0:
fh = open(fout+’/’+str((cd_llh_traces[iter])[0]), ’w’)
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cPickle.dump(tssb, fh)
fh.close()

wts, nodes = tssb.get_mixture()
savetxt(out4,cd_llh_traces)
savetxt(out5,rate_est)

if iter >= 0:
wts, nodes = tssb.get_mixture()
for node in nodes:
data = node.get_data()
for datum in data:
for tp in arange(NTPS): freq[datum.name].append(float(round(node.params[tp],5)))

if (iter % 10) == 0:
print_top_trees(fout,out2,top_k)

glist = array(freq.keys(),str);glist.shape=(1,len(glist))
savetxt(out3,vstack((glist, array([freq[g] for g in freq.keys()]).T)),
fmt=’%s’,delimiter=’, ’)

if __name__ == "__main__":
run(sys.argv[1],sys.argv[16], sys.argv[2], sys.argv[3], sys.argv[4],
sys.argv[5],sys.argv[6],int(sys.argv[7]),int(sys.argv[8]),int(sys.argv[9]),
float(sys.argv[10]),float(sys.argv[11]),float(sys.argv[12]),
float(sys.argv[13]),float(sys.argv[14]),float(sys.argv[15]))
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#run(’data.txt’)

Main function for tree structure stick breaking process
class TSSB(object):

min_dp_alpha

= 1.0

max_dp_alpha

= 50.0

min_dp_gamma

= 1.0

max_dp_gamma

= 10.0

min_alpha_decay = 0.05
max_alpha_decay = 0.80

min_rate1 = -10.0
max_rate1 = 0.0
min_muup

=

0.0

max_muup

= 20.0

max_mudn

= 0.0

min_mudn = -20.0
min_std

= 0.1

min_std

= 20.0

def __init__(self, dp_alpha=1.0, dp_gamma=1.0, root_node=None, data=None,
normfactor1=None, normfactor2=None, purity1=None, purity2=None,
num_up=None, meandn=None, sddn=None, min_depth=0, max_depth=15,
alpha_decay=1.0, mu_dn=-2.0, std_dn=0.3, num_dn=0):
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if root_node is None:
raise Exception("Root node must be specified.")

self.num_up

= num_up

self.num_dn

= num_dn

self.min_depth

= min_depth

self.max_depth

= max_depth

self.dp_alpha

= dp_alpha

self.dp_gamma

= dp_gamma

self.alpha_decay = alpha_decay
self.data

= data

self.num_data

= 0 if data is None else len(data)#data.shape[0] #shankar

self.root

= { ’node’

: root_node,

’main’

: boundbeta(1.0, dp_alpha) if self.min_depth == 0 else 0.0,

’sticks’

: empty((0,1)),

’children’ : [] }
self._base_valueup=meandn
self._base_valuedn=mu_dn
self._stdup=sddn
self._stddn=std_dn
self.rate1up=self.rateprior(self._base_valueup,self._stdup, self.num_up)
self.rate1dn=self.rateprior(self._base_valuedn,self._stddn, self.num_dn)
self.rate1 = numpy.concatenate((self.rate1up, self.rate1dn))
self.rate=exp(self.rate1)
root_node.tssb = self
self.normf1=normfactor1
78

self.normf2=normfactor2
self.purity1=purity1
self.purity2=purity2
self.norm=[]
self.norm.append(self.normf1)
self.norm.append(self.normf2)
self.purity=[]
self.purity.append(self.purity1)
self.purity.append(self.purity2)

if False:
data_u

= rand(self.num_data)

self.assignments = []
for n in range(self.num_data):
(c, path) = self.find_node(data_u[n])
c.add_datum(n)
self.assignments.append(c)
else:
self.assignments = []
for n in range(self.num_data):
self.root[’node’].add_datum(n)
self.assignments.append(self.root[’node’])
def rateprior(self,base_value,std,dims):
m2 = std*randn(dims)+base_value
return m2
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def normpdfln(self,x,m,std):
norm1=-0.5*log(2*std*std*math.pi)
norm2=-((x-m)**2)/(2*std*std)
#print(’result’,x,m,std,norm1+norm2)
return norm1+norm2

def resample_mhypers(self, dp_rate1=True):

def dp_m_llh(logratio,n):
llh=0.0
llh=llh+(self.assignments[n].logprob(self.data[n:n+1],exp(logratio),
self.norm,self.purity)+self.normpdfln(self._base_valueup,logratio,self._stdup))
return llh

for n in range(self.num_up):
if self.rate1[n]>self.max_rate1:
self.rate1[n]=self.max_rate1
if self.rate1[n]<self.min_rate1:
self.rate1[n]=self.min_rate1
if self.rate1[n]:
upper = self.max_rate1
lower = self.min_rate1
llh_s = log(rand()) + dp_m_llh(self.rate1[n],n)
while True:
new_rate1 = (upper-lower)*rand() + lower
new_llh

= dp_m_llh(new_rate1,n)
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if new_llh > llh_s:
break
elif new_rate1 < self.rate1[n]:
lower = new_rate1
elif new_rate1 > self.rate1[n]:
upper = new_rate1
else:
print("slice")
raise Exception("Slice sampler shrank to zero!")
self.rate1[n] = new_rate1
self.rate[n]=exp(self.rate1[n])

def add_data(self, data):
(weights, nodes) = self.get_mixture()
num_new_data = len(data)#data.shape[0] #shankar
for n in range(num_new_data):
logprobs = []
for k, node in enumerate(nodes):
#print(’self.rate[n]=’,self.rate[n])
logprobs.append(log(weights[k])+node.logprob(data[n],self.rate[n]),
self.norm,self.purity )
logprobs = array(logprobs)
probs

= exp(logprobs - logsumexp(logprobs))

best_k

= sum( rand() > cumsum(probs) )

nodes[best_k].add_datum(n + self.num_data)
self.assignments.append(nodes[best_k])
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self.data = vstack([self.data, data])
self.num_data += num_new_data

def complete_data_log_likelihood(self):
weights, nodes = self.get_mixture();
llhs = 0.0
for n in range(self.num_data):
llhs=llhs+self.assignments[n].logprob(self.data[n:n+1],self.rate[n],
self.norm,self.purity)
#print(’llhs’,llhs,self.rate[n],self.assignments[n].logprob(self.data[n:n+1],
self.rate[n],self.norm))
return llhs

def print_graph(self, fh, base_width=5000, min_width=5):
print >>fh, """graph: { title:

"TSSB Graph"

portsharing:

no

\

smanhattanedges:

yes

\

equalydist:

yes

\

layout_algorithm: tree

\

node.fontname:

"helvR8"

\

node.height:

25 """

\

print >>fh, """node: { label:"%0.5f" title:"%s" width:%d}""" \
% (self.root[’main’], "X", max(int(self.root[’main’]*base_width), min_width))
def descend(root, name, mass):
total

= 0.0
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edges

= sticks_to_edges(root[’sticks’])

weights = diff(hstack([0.0, edges]))
for i, child in enumerate(root[’children’]):
child_name = "%s-%d" % (name, i)
child_mass = mass * weights[i] * child[’main’]
print >>fh, """node: {

label:"%0.5f" title:"%s" width:%d}""" \

% (child_mass, child_name, max(int(child_mass*base_width),min_width))
print >>fh, """edge: { source:"%s" target:"%s" anchor:1}""" % (name, child_name)
total += child_mass + descend(child, child_name, mass*weights[i]*
(1.0-child[’main’]))
return total
print >>fh, """}"""

Main function for plot tree structures

def print_top_trees(fdir,fout,k=5):
global ctr;
flist = os.listdir(fdir);
if sum([flist[i]==’.DS_Store’ for i in arange(len(flist))]):
flist.remove(’.DS_Store’)
if len(flist)<k:k=len(flist)
flist = sort(array(flist,float))[::-1][:k]
fout = open(fout,’w’)
for fname in flist:
ctr=0
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print_best_tree(fdir+’/’+str(fname),fout)
fout.close()

def print_best_tree(fin,fout):
fh = open(fin)
tssb = cPickle.load(fh)
fh.close()

wts, nodes = tssb.get_mixture()
w = dict([(n[1], n[0]) for n in zip(wts,nodes)])
nnodes = sum( [ 1 for node in nodes if len(node.get_data()) ] )

t = Tree();t.name=’0’
fout.write(’id, \t phi, \t nChildren, \t nGenes, \t genes, \t parent \n’)
print_node2(tssb.root,None,t,w,fout)
fout.write(’\n\n’)
fout.write(t.get_ascii(show_internal=True))
fout.write(’\n\n’)
fout.write(’Number of non-empty nodes in the tree: ’ +repr(nnodes))
fout.write(’\n\n\n’)

def print_node2(node, parent,tree,wts,fout):
global ctr;
num_data = node[’node’].num_data()
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if len(node[’children’])==0 and node[’node’].params<0.1: return

node_name

= ctr

genes = node[’node’].get_data()
gnames = ’’
if len(genes)>0:
gnames = genes[0].name
for g in arange(1,len(genes)):
gnames = gnames + ’; ’ + genes[g].name;

out_str=str(node_name)+’,\t’+str(around(node[’node’].params,3))+’,\t’+
str(len(node[’children’])) + ’,\t’ + str(len(genes)) + ’,\t’ + gnames + ’,\t’ +
str(parent)+’\n’
fout.write(out_str)

for child in node[’children’]:
if len(child[’node’].get_data())>0 and child[’node’].params>=0.1:
ctr+=1;
name_string = str(ctr) #+’(’+str(node_name)+’)’
print_node2(child, node_name,tree.add_child(name=name_string),wts,fout)

print_top_trees(’trees_outrate’,’fout’,k=1)
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